Chia-Feng Lu

Practice Details

• Languages
  English
  Japanese
  Chinese (Cantonese)
  Chinese (M
  arin)
  Taiwanese
• Firm Information
  Position

  Shareholder

  Firm Name

  Greenberg Traurig, LLP
• Representative Cases & Transactions
  Cases

  Experience: Representative Matters: Represented a leading pharma's acquisition of a NASDAQ-listed biotech company focusing on cancer therapies
  treatments in a cash tender offer followed by a merger for a total equity value of $2.4 billion, as well as relevant post-merger work.
  Advised a leading Boston-based biotechnology company on the regulatory strategy of its leading neurodegenerative medicine.
  Advised a leading semiconductor company on its joint-venture
  collaboration project
  resulting possible export control
  trade issues.
  Advised a leading bioventure in anti-infectious diseases area on its dispute with global contract research organization.
  Advised a leading IoT company on development of its compliance program across multiple jurisdictions in the U.S.
  in Europe from regulatory, antitrust,
  data privacy perspectives.
  Advised a bioventure on its license of its early-stage asset in Kennedy's disease to a NASDAQ-listed biotech company.
  Advised a leading pharmaceutical company on the co-development strategy for a drug-biologic combination regime from the regulatory
  market access perspectives in the U.S.
  in Europe.
  Advised a leading pharmaceutical company on its introduction of AI tool in empowerment of its drug discovery activity
  on its partnership with such AI company for the license.
  Advised on a leading technology conglomerate on its acquisition of a laboratory-developed testing company in the United States.
  Advised a leading biotech company on its risk-sharing clinical trial collaboration with a contract research organization on its lead ophthalmology product, including the investment from such contract research organization.
  Advised a leading pharmaceutical company on its novel cell therapy portfolio's regulatory strategy, policy advocacies, life cycle management approach,
  strategic partnership transactions in multiple jurisdictions.
  Represented a U.S.
  a Japanese pharmaceutical company in their co-developed cancer immunotherapy regarding legal matters related to the product launch in multiple jurisdictions.
  Advised on various legal
  regulatory issues underlying the product development of a digital health product, including its AI component, developed by a U.S. technology conglomerate in more than thirty jurisdictions.
  Represented a U.S. global biotechnology company in its contract manufacturing partnership negotiation with several contract development
  manufacturing organizations for its CAR-T therapy in multiple jurisdictions.
  Led the regulatory, policy,
  legal advisory to a leading U.S. biotechnology company's launch of SiRNA therapy in several jurisdictions.
  Led a strategic investment in a microbio company together with leading venture capitals
  the Bill & Melinda Gates Foundation.
  Advised a Japanese conglomerate on its acquisition of a U.S. diagnostic company to increase its precision medicine capacity in the US, the following post-merger integration, as well as the relevant FDA regulatory issues of the development of the novel diagnostics.
  Represented a global biotech company to resolve its dispute with its regional partner on a co-promotion partnership of its blockbuster.
  Led the initiative to prepare
  implement global policies
  procedures, such as anti-bribery, sponsorship, donation, fair market value, transparency, interactions with the stakeholders, cross-border data transfer, hotline/helpline, on behalf of multiple top global pharmaceutical companies.
  Defended a lead biotechnology company against a government's investigation concerning its unfair competition practices, which was raised from its competitor.
  Advised a U.S. health care conglomerate on numerous legal issues surrounding its establishment of an innovation incubation center affiliated with a health care institution in Gulf area.
  Advised on a leading biotechnology company's authorized generic strategy of its blockbuster cancer product.
  Served as the external general counsel to numerous biotech or emerging technology companies in the U.S.
  in Europe.
  The above representations were h
  led by Mr. Lu prior to his joining Greenberg Traurig, LLP.
  In-House Experience: Takeda Pharmaceutical Company
  Celgene
• Additional Links
  https://www.gtlaw.com/en/professionals/l/lu-chia-feng